We are live on ! Find out more
AERI

Aerie Pharmaceuticals

Delisted

AERI was delisted on the 18th of November, 2022.

156 hedge funds and large institutions have $703M invested in Aerie Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 52 funds opening new positions, 47 increasing their positions, 45 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% more capital invested

Capital invested by funds: $354M → $703M (+$350M)

58% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 33

34% more call options, than puts

Call options by funds: $610K | Put options by funds: $454K

14% more funds holding

Funds holding: 137156 (+19)

4% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 45

Holders
156
Holders Change
+19
Holders Change %
+13.87%
% of All Funds
2.69%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.05%
New
52
Increased
47
Reduced
45
Closed
33
Calls
$610K
Puts
$454K
Net Calls
+$156K
Net Calls Change
+$65K

AERI Hedge Fund Activity: Q3 2022 in Review

156 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2022, worth a combined $703M — up 99% from $354M a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new AERI positions and 33 closed out — a net gain of 19 holders — while 47 added to existing stakes and 45 trimmed.

The largest buyer was Water Island Capital, opening a new position worth an estimated $24.2M. The largest seller was Bank of America, cutting an estimated $17.7M.

  • 156 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2022, up from 137 in Q2 2022.
  • Funds reported $703M of Aerie Pharmaceuticals stock for Q3 2022, up 99% quarter-over-quarter.
  • 52 funds opened new Aerie Pharmaceuticals positions in Q3 2022 and 33 closed out, a net change of +19 holders.
  • The largest Aerie Pharmaceuticals buyer in Q3 2022 was Water Island Capital, an estimated $24.2M added.
  • The largest Aerie Pharmaceuticals seller in Q3 2022 was Bank of America, an estimated $17.7M sold.

Based on aggregated 13F filings for Q3 2022.